Major Events - Four Seasons Pharmaceutical (00460) invests in Swiss Suisselle to accelerate global medical aesthetics business expansion [1] - Basilea Pharmaceutica-B (02616) to announce Phase I dose-escalation clinical data for PD-1/VEGF/CTLA-4 triple antibody and latest research design for ROR1 ADC [1] - Hengrui Medicine (01276) subsidiary receives drug clinical trial approval notice [1] - Huajian Medical (01931) acquires U.S. property and establishes U.S. subsidiary ETHK BANK to promote stablecoins and intellectual property securitization in the U.S. [1] - China National Pharmaceutical Group (01177): TQB2102 "HER2 dual antibody ADC" included in breakthrough therapy designation program [1] Operating Performance - 361 Degrees (01361): Retail sales of 361° main brand products in Q3 increased by approximately 10% year-on-year [1] - Xinhua Insurance (01336) expects net profit attributable to shareholders for the first three quarters to increase by 45% to 65% year-on-year [1] - Country Garden (02007) achieved contract sales amounting to approximately 2.58 billion yuan in September [1] - Dekang Agriculture and Animal Husbandry (02419) sold approximately 7.55 million pigs and generated sales revenue of approximately 14.28 billion yuan in the first nine months [1] - Longfor Group (00960) achieved total contract sales amount of 50.75 billion yuan in the first nine months [1]